Funobactam Medicine 04 December 2025 Extended indication Treatment of infections caused by Gram-negative organisms (in combination with imipenem and cilastatin). Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Funobactam Domain Infectious diseases Reason of inclusion New medicine (specialité) Main indication Bacterial infections Extended indication Treatment of infections caused by Gram-negative organisms (in combination with imipenem and cilastatin). Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Evopoint Portfolio holder Evopoint Mechanism of action Route of administration Intravenous Therapeutical formulation Unknown Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date March 2026 Expected Registration April 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Tijdslijn op basis van IHSI-inschatting. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT05204368; NCT05204563 (REITAB-2) Additional remarks Imipenem/cilastatine 500mg/500mg in combinatie met funobactam 250mg intraveneus elke zes uur toegediend over 30 minuten. Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks